Moderate to severe TBI is associated with elevated malignant brain tumor risk
1. In this retrospective cohort study, moderate to severe traumatic brain injury (TBI) was associated with an increased risk of ...
Tag: oncology
2 Minute Medicine Rewind September 1, 2025
β-Blocker Use and Health Status Among Patients With Heart Failure With Preserved Ejection Fraction 1. In patients with heart failure ...
Switching to camizestrant after ESR1 mutation detection prolongs progression free survival in advanced breast cancer
1. In patients with ER-positive, HER2-negative advanced breast cancer who developed an ESR1 mutation during first-line aromatase inhibitor plus CDK4/6 ...
Vepdegestrant extends progression-free survival in ER-positive, HER2-negative breast cancer
1. In this randomized controlled trial, vepdegestrant achieved a longer progression-free survival than fulvestrant in patients with advanced ER-positive, HER2-negative ...
Trastuzumab deruxtecan leads to longer overall survival than ramucirumab plus paclitaxel in HER2-positive gastric cancer
1. In this randomized controlled trial, among adults with HER2-positive unresectable or metastatic gastric cancer who had previously progressed on ...
Inavolisib lengthens progression-free survival time in HER2-negative advanced breast cancer
1. In this randomized controlled trial, in patients with PIK3CA-mutated advanced breast cancer, the addition of inavolisib to a palbociclib-fulvestrant ...
Pembrolizumab improves survival in locally advanced head and neck cancer
1. Among patients with locally advanced head and neck squamous-cell carcinoma (HNSCC), neoadjuvant and adjuvant pembrolizumab improved event-free survival compared ...
Extended aromatase inhibitor therapy reduces breast cancer recurrence in postmenopausal women
1. Invasive breast cancer recurrence was significantly reduced with extended aromatase inhibitor therapy. 2. No significant reduction was noted for ...
Talazoparib and enzalutamide improve survival in metastatic castration-resistant prostate cancer
1. Progression-free survival and overall survival were significantly greater in the combination therapy group compared to enzalutamide alone. 2. Anemia ...
mFOLFIRINOX may have a limited role in pancreatic cancer in Phase II/III trial
1. In patients with metastatic pancreatic cancer, neither modified fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) or S-1, irinotecan and oxaliplatin ...
